DARUNAVIR | A206288 | CIPLA LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D.N.J. | 2014-08-13 | Terminated 2018-08-29 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$2.27
per ea
Lowest NADAC/Unit
$1.18
per ea
Brand NDCs
0
Generic NDCs
6
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 60687081921DARUNAVIR 800 MG TABLET | $2.27 | EA | Generic | — | 2026-06-17 |
| 76282073830DARUNAVIR 800 MG TABLET | $2.27 | EA | Generic | — | 2026-06-17 |
| 69097024402DARUNAVIR 800 MG TABLET | $2.27 | EA | Generic | — | 2026-06-17 |
| 60687080821DARUNAVIR 600 MG TABLET | $1.18 | EA | Generic | — | 2026-06-17 |
| 76282073760DARUNAVIR 600 MG TABLET | $1.18 | EA | Generic | — | 2026-06-17 |
| 69097024803DARUNAVIR 600 MG TABLET | $1.18 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.